需要金币，哈哈，找了下电脑里也没啥书，上传个以前的小组作业，自我感觉做的挺好，有需要的人可以看看，我也顺便赚点钱哈哈
Abstract: This studymakes an attempt to find out different risks that an organization faces ingeneral and the European Union’s requirements of discloser of risk management.It also attempt to classify and evaluate different risks, investigate hedgingstrategies, determining liquidity level and recommend a target liquidity level,finding a risk management process and rating risk of AstraZeneca Plc, PfizerInc and Ondine Biopharma Corp. (OBP). It has been acknowledged that total riskcan be classified in two major categories, systematic and unsystematic risks.The European Union has accepted International Financial Reporting Standard(IFRS) and section 7 of the IFRS does include the policies and guidelines ofrisk management.
In the study risk has been classified according to four broad categories;operational, financial, strategic and hazard and it has been observed that the organizationsdo not disclose all types of risks in their annual report. Based on fundamentaland beta calculation, it is fair to say that Pfizer Inc has the lowest risk,that AstraZeneca Plc has a more sound position than the market, and that OndineBiopharma Corp has a very high risk due to uncertainty of further operation. Inliquidity analysis it has been identified that Pfizer Inc is more conservativethan others, whereas AstraZeneca Plc is very aggressive and growing faster. Apossible risk management committee and strategy has been suggested for betterassurance to stakeholders.
To conclude the study, categories of risk and a rating model have beenused. It has been observed that Pfizer Inc and AstraZeneca Plc have a category risk of ‘A’ and an ‘excellent customer’ rating. OndineBiopharma Corp has a category risk of ‘B’ but it has ‘credit stop’ rating dueto negative profitability, poor management, and higher risk than themarket.
Key words: risk, liquidity,risk management.